Souhaitez-vous accéder aux communiqués récents ?

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist

Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2026" report has been added to ResearchAndMarkets.com's offering. Whether...

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservati

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

IRVING, Texas, Dec. 31, 2025 (GLOBE NEWSWIRE) -- As 2025 ends, BioNTX reflects on a year—and the close of the first quarter of the 21st century—defined by accelerated growth, expanded engagement,...

Plano, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- As 2025 comes to a close, BioNTX reflects on a year of innovation, growth, and achievement across North Texas’ life science ecosystem, highlighted by...